Sign Out
Clear to slightly opalescent, colorless to pale brown, sterile liquid for intravenous (i.v.) infusion.
Active ingredient: Bevacizumab (humanised anti-VEGF monoclonal antibody).
KRABEVA is supplied in 100 mg and 400 mg vials containing 4 mL or 16 mL of Bevacizumab (25 mg/mL).
Each KRABEVA 100 mg in 4 mL vial contains 100 mg of bevacizumab concentrate for solution for intravenous infusion.
Each KRABEVA 400 mg in 16 mL vial contains 400 mg of bevacizumab concentrate for solution for intravenous infusion.
Sterile/Radioactive Statement: Sterile.
Excipients/Inactive Ingredients: Trehalose dihydrate, sodium phosphate, polysorbate, water for injection.
